Reinhard A. Becker

Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
.

Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL
.

Journal: International journal of clinical pharmacology and therapeutics
Published: October 30, 2018

In response to: Heise T, Nørskov M, Nosek L, Kaplan K, Famulla S and Haahr H. L. (2017) Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes. Diabetes Obes Metab. 2017;19:1032-1039.

In response to: Heise T, Nørskov M, Nosek L, Kaplan K, Famulla S and Haahr H. L. (2017) Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes. Diabetes Obes Metab. 2017;19:1032-1039.

Journal: Diabetes, obesity & metabolism
Published: February 05, 2018

Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.

Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.

Journal: Diabetes, obesity & metabolism
Published: August 31, 2016

Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL(-1) and Glargine 100 U mL (-1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study.

Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL(-1) and Glargine 100 U mL (-1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study.

Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: April 16, 2015

Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.

Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.

Journal: Diabetes/metabolism research and reviews
Published: December 23, 2014

Equivalent Recombinant Human Insulin Preparations and their Place in Therapy.

Equivalent Recombinant Human Insulin Preparations and their Place in Therapy.

Journal: European endocrinology
Published: September 03, 2014

New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.

New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.

Journal: Diabetes care
Published: August 24, 2014

Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study.

Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study.

Journal: Pediatric diabetes
Published: February 14, 2014

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.

Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.

Journal: Regulatory peptides
Published: November 28, 2012

Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.

Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes.

Journal: Diabetes care
Published: October 25, 2012
Showing 1-10 of 10

Last Updated: 09/26/2026